Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped up prior to trading on Friday . The stock had previously closed at $23.20, but opened at $27.54. Ascentage Pharma Group International shares last traded at $27.54, with a volume of 1,685 shares traded.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AAPG. Rodman & Renshaw assumed coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective for the company. Truist Financial set a $51.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, November 24th. BTIG Research began coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 price target on the stock. Oppenheimer began coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target on the stock. Finally, Piper Sandler initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, Ascentage Pharma Group International presently has an average rating of “Buy” and an average target price of $48.40.

Ascentage Pharma Group International Stock Performance

The stock’s 50 day simple moving average is $26.91 and its two-hundred day simple moving average is $33.84. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ascentage Pharma Group International in the 3rd quarter worth about $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth about $204,000. Chevy Chase Trust Holdings LLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter valued at approximately $227,000. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the 3rd quarter worth approximately $383,000. Finally, Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter valued at approximately $391,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.